WEST BEND, Wis., May 19, 2011 /PRNewswire/ -- Leading-edge Clinical Pharmacology and Cardiac Core Lab provider, Spaulding Clinical Research, LLC proudly receives the 2011 IQ (Innovation Quotient) award sponsored by the Marquette University's Graduate School of Management and BizTimes Media, a magazine dedicated to providing Wisconsin business leaders news, analysis and strategic insights. The revolutionary Spaulding IQ(SM) electrocardiogram was recognized with nine other award winners for innovative, clever, and unique products, services, or processes.
The Spaulding IQ is a revolutionary 12-lead electrocardiographic machine, about the size of a hockey puck, which instead of keyboards and LCD displays, utilizes a microphone and voice-print biometrics to identify the patient. IQ is capable of recording five minutes of data versus the standard 10 seconds of traditional ECG devices. The Spaulding IQ was designed to be a cost-effective solution for pharmaceutical clients that have not centralized ECG drug trial information due to cost and complexity. The device is part of a total ECG Solution, from Spaulding Clinical, for clinical trials where cardiac safety data is required.
Randol Spaulding, CEO and founder of Spaulding Clinical, commented, "It is difficult to put into words how proud I am of the teamwork and effort it has taken to move the Spaulding IQ product from vision through approval. It is a great achievement and only fitting that we, the makers of IQ, win the IQ Award. We are honored to be recognized by Marquette and BizTimes Media."
Spaulding Clinical will be demonstrating the cutting edge "Spaulding IQ" ECG device and Core ECG Lab Solutions from June 19 – 22, 2011 in booth 1905 at the DIA (Drug Information Association) meeting in Chicago, IL. To learn more about how Spaulding can assist with your Clinical Pharmacology programs, Pharmacokinetic analysis, or ECG Core lab programs, please contact us at SpauldingPK@spauldingclinical.com or 262-306-3331.
About Spaulding Clinical
Spaulding Clinical Research, LLC (www.spauldingclinical.com) is a Clinical Pharmacology Research Unit and Cardiac Core Lab that offers a full range of global services from study design through study execution/conduct, data management, statistical analysis, and clinical summary/expert reporting. Spaulding has extensive experience conducting TQT, first-in-human, multiple rising dose, bioavailability/bioequivalence, drug interaction, and food effect studies. As a Phase 1-4 Core Lab provider, Spaulding offers the complete suite of equipment provisioning and electrocardiogram over-reading services with state-of-the-art technologies and expertly trained cardiologists.
|SOURCE Spaulding Clinical Research, LLC|
Copyright©2010 PR Newswire.
All rights reserved